Pharmaceutical composition for preventing or treating blood-brain barrier injury after cerebral ischemia and application thereof

By using ANXA5 monomer or dimer to target the PS exposure of astrocytes after cerebral ischemia, the problem of poor treatment effect of blood-brain barrier injury in the prior art is solved, and effective protection of the blood-brain barrier is achieved , reducing cerebral edema and vascular leakage.

CN118987171APending Publication Date: 2024-11-22JIANGSU TARGET BIOMEDICINE RES INST
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411073158.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-06
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The prior art has limited effectiveness in treating blood-brain barrier damage after cerebral ischemia, and lacks effective targeted treatment strategies. In particular, the research on the behavior of astrocytes after ischemia and the mechanism of blood-brain barrier damage is relatively limited. .

Method used

Using phosphatidylserine (PS) binding protein Annexin A5 (ANXA5) monomer or dimer as a pharmaceutical composition, using disulfide bond-linked C-terminal cysteine ANXA5 dimer formed by acid residues to improve affinity and protect blood-brain barrier integrity.

Benefits of technology

ANXA5 dimer significantly improves the targeted effect on PS exposure of astrocytes, reduces the damage to the blood-brain barrier, reduces vascular leakage and cerebral edema, and shows higher therapeutic efficacy after cerebral ischemia.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118987171A_ABST
    Figure CN118987171A_ABST
Patent Text Reader

Abstract

The invention discloses a pharmaceutical composition for preventing or treating blood-brain barrier injury after cerebral ischemia and application of the pharmaceutical composition, and particularly relates to a pharmaceutical composition for preventing or treating blood-brain barrier injury after cerebral ischemia. The pharmaceutical composition for preventing or treating blood-brain barrier injury after cerebral ischemia comprises phosphatidylserine (PS) binding protein as an active ingredient, and the PS binding protein has high affinity to bind to PS exsertion on astrocytes. And the PS binding protein is an Annexin A5 (ANXA5) dimer. The ANXA5 dimer disclosed by the invention shows higher efficacy in the aspect of targeting astrocyte PS exposure so as to improve blood-brain barrier destruction after cerebral ischemia.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of biopharmaceuticals, and in particular to a pharmaceutical composition for preventing or treating blood-brain barrier damage after cerebral ischemia and an application thereof. Background Art

[0002] Studies have shown that stroke has been one of the leading causes of disability and death worldwide over the past 30 years (Lindsay MP, et al. International Journal of Stroke, 2019, 14(8): 806-817.). As the population ages, this problem is expected to continue to worsen in the coming decades. In addition to supportive care, treatment options for cerebral ischemia remain limited, currently mainly including thrombolysis and interventional thrombectomy. However, due to the relatively short treatment time window of thrombolysis and thrombectomy and the potential for serious complications, very few stroke patients can benefit from these treatments (Qureshi N, et al. New England Journal of Medicine, 1996, 334(21): 1406.). The main complications of thrombectomy include reperfusion hemorrhage and cerebral edema, and these life-threatening complications are likely due to the destruction of the blood-brain barrier (Lindsay E, et al. Journal of Emergency Medicine, 2018, 54(4): 583-584.). In addition, damage to the blood-brain barrier also leads to increased mortality in stroke patients who do not receive thrombectomy. Therefore, there is an urgent need to develop new therapeutic strategies to improve the status of blood-brain barrier disruption.

[0003] Astrocytes play a key role in maintaining the integrity of the blood-brain barrier. Astrocytes help maintain the structure and function of the blood-brain barrier through close contact and signal transmission with vascular endothelial cells. In vitro and in vivo studies have shown that neurons are one of the most sensitive cell types in the brain and are prone to damage and death under ischemic conditions (Alvarez JI, et al. Glia, 2013, 61 (12): 1939-1958.). In contrast, astrocytes show stronger resistance and can maintain their functions for a longer time in an ischemic environment. Astrocytes can not only survive in an ischemic environment, but also protect neurons from damage to a certain extent. However, research on how astrocytes participate in the destruction of the blood-brain barrier after cerebral ischemia is still very limited. Existing studies suggest that astrocytes may undergo morphological and functional changes after ischemia, and these changes may have a negative impact on the integrity of the blood-brain barrier (Cheng J, et al. Frontiers in Pharmacology, 2023, 14: 1122527.). Therefore, further study of the behavior of astrocytes after cerebral ischemia and their effects on the blood-brain barrier is crucial for understanding the pathological mechanisms of cerebral ischemia and developing new therapeutic strategies.

[0004] Phosphatidylserine (PS) is asymmetrically distributed on the cell membrane in normal cells, mainly confined to the inner layer. This asymmetric distribution is essential for the normal function of cells. However, when cells are stressed or in the process of dying, PS will move to the outer layer of the cell membrane, becoming a clear feature of dying or stressed cells. After ischemic stroke, PS exposure has been shown to exist in dying neurons, which reveals a key step in membrane structure changes during cell death. Although we understand the phenomenon of PS exposure in neurons after ischemic stroke, other cell types exposed to PS after cerebral ischemia have not been systematically studied. Understanding the exposure of PS in different types of cells after cerebral ischemia is of great significance for a comprehensive understanding of the mechanism of brain injury and the development of effective treatment strategies. A large number of literature reports show that the amount of exposed PS increases, making it an attractive biomarker for targeted therapy (Schutters K, et al. Springer Open Choice, 2010, 15: 1072-1082.). In this regard, ANXA5 shows great potential. ANXA5 belongs to the annexin family and can specifically bind to exposed PS on the cell surface in a calcium-dependent manner (Kang TH, et al. Nature Communications, 2020, 11(1): 1137.). This property makes ANXA5 an ideal tool for identifying and targeting cells that expose PS.

[0005] In summary, although PS exposure is a widely studied phenomenon for the diagnosis of cell death, it is still unclear whether PS can be a target for improving the integrity of the blood-brain barrier after cerebral ischemia. Studies have shown that ANXA5 exists in cells as a mixture of monomers and polymers under physiological conditions, and the affinity of ANXA5 and PS is positively correlated with the molecular weight of ANXA5. The N-terminal region of annexin is highly variable and is thought to be related to the specific properties of annexin, but the C-terminal region is highly conserved and is thought to be related to phospholipid membrane binding, so the addition of a disulfide bond at the C-terminus helps to form ANXA5 dimers with improved affinity for PS. Summary of the invention

[0006] In order to solve the problems of the prior art, the present invention provides a pharmaceutical composition for preventing or treating blood-brain barrier damage after cerebral ischemia and application thereof.

[0007] To achieve the above application purpose, the technical solution adopted in this application is as follows: A pharmaceutical composition for preventing or treating blood-brain barrier damage after cerebral ischemia of the present invention, the pharmaceutical composition for preventing or treating blood-brain barrier damage after cerebral ischemia comprises a phosphatidylserine PS binding protein as an active ingredient, the PS binding protein comprises Annexin A5 (ANXA5) monomer or Annexin A5 (ANXA5) dimer, the PS binding protein has high affinity ANXA5 monomer and dimer can bind to PS exposed on astrocytes, thereby exerting a therapeutic effect. The amino acid sequence of the ANXA5 monomer is shown in SEQ ID NO.1, and the amino acid sequence of the ANXA5 dimer is shown in SEQ ID NO.2.

[0008] Furthermore, ANXA5 dimers were formed through disulfide-linked C-terminal cysteine ​​residues to target PS externalization on astrocytes.

[0009] Furthermore, it contains one or more pharmaceutically acceptable carriers or diluents.

[0010] The present invention provides a method for treating blood-brain barrier damage after cerebral ischemia using a pharmaceutical composition, which is administered by tail vein injection. The dosage is adjusted according to the patient's weight and the severity of the disease. Cerebral ischemia is diagnosed before treatment, and a treatment plan is determined based on the diagnosis results.

[0011] The method of the present invention for evaluating the degree of blood-brain barrier damage after cerebral ischemia evaluates the degree of damage by detecting the level of PS exposure in brain tissue.

[0012] Furthermore, fluorescently labeled ANXA5 or its dimer was used as an imaging agent for PS exposure.

[0013] The method of the present invention for detecting PS exposure of astrocytes after cerebral ischemia uses a probe combining ANXA5 or its dimer with a fluorescent marker for detection.

[0014] Furthermore, PS-exposed astrocytes were observed and quantitatively analyzed by fluorescence microscopy.

[0015] The pharmaceutical composition of the present invention is used in preparing a drug for preventing or treating and alleviating blood-brain barrier damage after cerebral ischemia.

[0016] Beneficial effects: The present invention protects the integrity of the blood-brain barrier after ischemic stroke by targeting PS exposure on astrocytes. The ANXA5 dimer of the present invention shows higher efficacy in targeting PS exposure on astrocytes to improve the destruction of the blood-brain barrier after cerebral ischemia.

[0017] Compared with the prior art, the present invention has the following advantages: (1) The present invention separates ANXA5 monomer and dimer proteins in vitro for the first time, which has a high reference value for studying the correlation between the aggregation state of membrane annexin and diseases.

[0018] (2) The PS exposure on the surface of astrocytes was found and confirmed in the early acute stage of ischemic stroke, which was earlier than the PS exposure on neurons. The ANXA5 dimer protein provided by the present invention has more significant annexin properties and better properties for treating ischemic stroke.

[0019] (3) A disulfide-linked ANXA5 dimer of the present invention is a novel ANXA5 protein with higher affinity for PS exposure by introducing cysteine ​​at the C-terminus. Compared with ANXA5 monomer, ANXA5 dimer shows higher efficacy in targeting PS exposure of astrocytes to improve blood-brain barrier disruption after cerebral ischemia.

[0020] (4) The effectiveness of ANXA5 dimer in alleviating BBB damage after ischemic stroke was verified through in vivo and in vitro experiments, including reducing the leakage of vascular tracer EB and reducing brain edema. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] In order to more clearly illustrate the technical solutions in the embodiments of the present application, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present application. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.

[0022] Figure 1 This is a conceptual diagram of the design of the ANXA5 monomer and dimer of the present invention.

[0023] Figure 2 This is the separation result of ANXA5 monomer and dimer of the present invention.

[0024] Figure 3 It is a structural characteristic diagram of the ANXA5 monomer and dimer of the present invention.

[0025] Figure 4 Schematic diagram of amino acids that interact with calcium ions in the ANXA5 monomer and dimer of the present invention.

[0026] Among them, (A)(B): calcium ion distribution diagram in ANXA5 monomer; (C)(D): calcium ion distribution diagram in ANXA5 dimer.

[0027] Figure 5 Fig. 5 is the affinity fitting curve of ANXA5 monomer and dimer of the present invention to PS membrane.

[0028] Figure 6 Diagram of the interaction of ANXA5 and dimers with phosphatidylserine (PS) of the present invention.

[0029] Figure 7 The flow cytometric analysis diagram of apoptotic cells labeled with the ANXA5-Alexa FluorTM 555 and ANXA5m-Alexa FluorTM 555 probes of the present invention is shown.

[0030] Figure 8 The present invention shows the results of PS exposure on the surface of neurons and astrocytes in the early acute phase after cerebral ischemia. (A): Mice were treated with ANXA5-Alexa FluorTM 555 or mutant ANXA5-Alexa FluorTM 555 after cerebral ischemia-reperfusion. 24 hours later, ANXA5 red fluorescence showed PS exposure in the ischemic cortex; (B): Representative images of co-localization of PS (marker ANXA5) and neurons (marker NeuN) in the ischemic cortex 24 hours after cerebral ischemia; (C): Representative images of co-localization of PS (marker ANXA5) and microglia / macrophages (marker Iba1) 24 hours after cerebral ischemia; (D): Representative images of co-localization of PS (marker ANXA5) and astrocytes (marker GFAP); (E): Quantitative data statistics of co-localization of PS (marker ANXA5) with cell-specific markers Neun, IBAI and GFAP, n=3.

[0031] Fig. 9The results of PS exposure on the surface of primary astrocytes after in vitro oxygen-glucose deprivation (OGD) of the present invention are shown in Figure 1. (A): Oxygen-glucose deprivation (OGD) induces PS exposure (marker ANXA5) in primary astrocytes; (B): Quantitative analysis of the coexistence of PS exposure (marker ANXA5) and astrocyte specificity (marker GFAP), n=3.

[0032] Fig.10 Figure 1 is a diagram of the phagocytosis of PS-exposed astrocytes by microglia in the ischemic brain of the present invention. (A) Microglia lineage tracing mice (Cx3cr1CreERT2: Rosa26) received fluorescently labeled ANXA5 (ANXA5-EGFP) via tail vein injection 24 hours or 48 hours after cerebral ischemia. Representative images show that tdTomato (tdT+) microglia in the ischemic cortex phagocytized ANXA5-labeled astrocyte fragments; (B) Quantitative analysis of microglia phagocytosis of astrocyte fragments, n=3.

[0033] Fig.11 The PS exposure diagram of ANXA5 monomer and dimer targeting astrocytes in ischemic brain of the present invention. Among them, (A): a typical image of ANXA5 red fluorescence co-localization with astrocytes (marker GFAP) 24 hours after reperfusion; (B): quantitative analysis of ANXA5 red fluorescence co-localization with astrocytes (marker GFAP), n=3.

[0034] Fig.12 The ANXA5 monomer and dimer of the present invention improve the leakage of brain blood vessels after cerebral ischemia.

[0035] Among them, (A): mice were treated with ANXA5 monomer and dimer at a dose of 0.75 mg / kg after reperfusion, and the representative image of Evans blue leakage into ischemic brain tissue 48 hours later; (B): quantitative analysis of Evans blue leakage into ischemic brain tissue 48 hours later; (C): mice were treated with ANXA5 monomer and dimer at a dose of 1.0 mg / kg after reperfusion, and the representative image of Evans blue leakage into ischemic brain tissue 48 hours later; (D): quantitative analysis of Evans blue leakage into ischemic brain tissue 48 hours later, n=6.

[0036] Fig.13 The diagram shows the effects of different doses of ANXA5 monomer and dimer of the present invention on improving brain edema after cerebral ischemia, n=5.

[0037] Fig.14Figure 1 shows that the ANXA5 monomer and dimer of the present invention mechanically maintain astrocyte-vascular coupling after cerebral ischemia. (A) Representative images of ANXA5 monomer and dimer inhibiting microglial phagocytosis of astrocytes treated with OGD, and red arrows indicate the fragmentation of astrocytes treated with OGD, n = 3; (B) (C) Representative images and quantitative analysis of co-localization of AQP4 and CD31 24 hours after reperfusion after cerebral ischemia in mice, n = 3. In the ischemic brain, the co-localization of AQP4 and CD31 (specific markers of vascular endothelial cells) is used to indicate the coupling of astrocytes with blood vessels; (D) (E) Representative images and quantitative data of leaky blood vessels 24 hours after cerebral ischemia and reperfusion in mice, n = 3. Leaky blood vessels were assessed by double labeling of CD31 and extravascular fibrinogen to indicate the coupling of astrocytes with blood vessels. DETAILED DESCRIPTION

[0038] In order to make the technical problems, technical solutions and beneficial effects to be solved by the present application more clearly understood, the present application is further described in detail below in conjunction with the embodiments. It should be understood that the specific embodiments described herein are only used to explain the present application and are not used to limit the present application.

[0039] The following examples are provided to help further understand the present invention, but the present invention is not limited thereto.

[0040] The first aspect of the present invention is to provide a pharmaceutical composition for preventing or treating blood-brain barrier damage after cerebral ischemia. The pharmaceutical composition for preventing or treating blood-brain barrier damage after cerebral ischemia contains a phosphatidylserine (PS) binding protein as an active ingredient. The PS binding protein is an Annexin A5 (ANXA5) dimer. The PS binding protein has high affinity and binds to the exposed PS on astrocytes.

[0041] In some embodiments, ANXA5 dimers are formed through disulfide-linked C-terminal cysteine ​​residues to target PS externalization on astrocytes.

[0042] In some embodiments, one or more pharmaceutically acceptable carriers or diluents are included.

[0043] The second aspect of the present invention is to provide a method for treating blood-brain barrier damage after cerebral ischemia using a pharmaceutical composition, which is administered by tail vein injection. The dosage is adjusted according to the patient's weight and severity of the disease. Before treatment, a diagnosis of cerebral ischemia is performed, and a treatment plan is determined based on the diagnosis results.

[0044] The third aspect of the present invention is to provide a method for evaluating the degree of blood-brain barrier damage after cerebral ischemia, wherein the degree of damage is evaluated by detecting the level of PS exposure in brain tissue.

[0045] In some embodiments, fluorescently labeled ANXA5 or a dimer thereof is used as an imaging agent for PS exposure.

[0046] The fourth aspect of the present invention is to provide a method for detecting PS exposure of astrocytes after cerebral ischemia, using a probe in which ANXA5 or its dimer is combined with a fluorescent marker for detection.

[0047] In some embodiments, PS-exposed astrocytes are observed and quantified by fluorescence microscopy.

[0048] The fifth aspect of the present invention is to provide a pharmaceutical composition for use in preparing a drug for preventing or treating blood-brain barrier damage after cerebral ischemia.

[0049] Example 1

[0050] Expression, purification and crystal structure analysis of ANXA5 monomer and dimer proteins

[0051] The designed ANXA5 monomer and dimer gene fragments ( Figure 1 The ANXA5-EGFP was ligated to the pET28a(+) expression vector and expressed in Escherichia coli BL21(DE3) cells. Protein expression was induced with 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) at 20°C for 18 h. For ANXA5 monomer and dimer proteins, they were stored in buffers containing 10 mM PB, 1 mM EDTA, pH 6.5 and 20 mM NaAc, 0.9% NaCl, pH 6.5, respectively. ANXA5-EGFP was purified by Ni-NTA affinity column and stored in Tris buffer containing 20 mM Tris, 30 mM NaCl, pH 8.5. The protein solution further purified by molecular sieves grew diffraction-quality crystals in a pool containing 0.2 M sodium chloride, 0.1 M 4-hydroxyethylpiperazineethanesulfonic acid pH 7.2 and 22% polyethylene glycol monomethyl ether 3000 at 16°C for 2 days. The crystals were diffracted and data processed, and the PDB IDs were 8H9Z (monomer) and 8GYC (dimer), respectively. The unit cell parameters of ANXA5 monomer and dimer are shown in Table 1.

[0052] Table 1

[0053]

[0054] Example 2

[0055] Preparation and characterization of ANXA5 monomer and dimer proteins

[0056] In order to obtain ANXA5 with improved affinity for PS, which is associated with increased molecular weight, dimeric ANXA5 may have higher affinity. In order to generate stable dimeric ANXA5, an additional cysteine ​​residue was added to the C-terminus of the ANXA5 protein, which was based on the structure of ANXA5 (PDB ID: 1HAK). Acidic solution can stabilize the dimer because it helps to store the dimeric protein in a low pH environment. In addition, in order to maintain the homogeneity of ANXA5 monomers, the use of EDTA is an effective method because EDTA has been shown to be very effective in preventing protein aggregation. Results of high performance liquid chromatography (HPLC) ( Figure 2 As shown in Figure 2, it was confirmed that the separation of ANXA5 monomers and dimers was successful and that they could be stably stored in the protective solution. Figure 3 As shown in the figure, the structures of ANXA5 monomer and dimer have similar basic structures. Each of the monomer and dimer ANXA5 molecules contains 4 repeating units (Repeat 1: residues 17-85, Repeat 2: residues 88-158, Repeat 3: residues 169-245, and Repeat 4: residues 247-321), and each repeating unit is composed of 5 helices, called A / B / C / D / E helices. However, the structure of dimeric ANXA5 contains two molecules of protein, connected by a pair of disulfide bonds formed by the sulfhydryl groups of 321Cys in chains A and B. There are obvious differences in the binding of calcium ions between ANXA5 monomer and dimer, as shown in the following figure. Figure 4 As shown. In monomeric ANXA5, 404CA and 407CA form polar interactions with amino acids in the core region, i.e., 404CA is fixed by 259Met, 264Thr, and 303Asp, and 407CA is fixed by 36Glu and 307Asp. In dimeric ANXA5, two calcium ions form polar interactions with amino acids; i.e., 401CA is fixed by 28Met, 30Gly, and 72Glu in chain A, and 402CA interacts with 138Glu and 139Asp in chain B.

[0057] Example 3

[0058] Affinity detection of ANXA5 monomer and dimer with PS

[0059] Apoptosis of Jurkat cells was induced by adding etoposide at a final concentration of 25 μM, and the cells were incubated at 37°C for 12 h. Then, the cells were harvested by centrifugation at 2,500 rpm for 5 min, washed twice, and resuspended to a cell density of 1 × 10 in binding buffer (10 mM HEPES, 140 mM NaCl, 2.5 mM CaCl2, pH 7.4). 6cells / mL. The ANXA5-EGFP probe was added to a final concentration of 400 nM and incubated with the cells on ice for 30 minutes. Afterwards, the monomer or dimer ANXA5 was diluted to different concentrations, and then 250 μL of protein dilution was added to 250 μL of cell suspension, so that the final concentrations were 9.77 nM, 19.53 nM, 39.06 nM, 78.13 nM, 156.25 nM, 312.5 nM, 625 nM, 1250 nM, 2500 nM, 5000 nM, and 10000 nM, respectively. After gently vortexing to mix, continue to incubate on ice for 30 minutes. Subsequently, the stained cells were analyzed using a flow cytometer (NovoCyte flow cytometer (ACEA@)). After the flow cytometry (FCM) analysis was completed, the R2 gated events in the FCM data were analyzed using FlowJo V10 software to determine the mean fluorescence intensity (MFI) of ANXA5-EGFP (FITC channel). The normalized MFI was calculated using the following formula: MFI of ANXA5-EGFP / maximum value of MFI*100 (%). The normalized MFI was then collected, and the reduction ratio of the normalized MFI relative to the control was used as the relative binding ratio of monomer or dimer ANXA5. Cells labeled with ANXA5-EGFP but not using ANXA5 monomer or dimer were negative controls. Based on the fitting curve of the relative binding rate of ANXA5 monomer or dimer and concentration, the relative affinity constant (Kd) was obtained. The results are shown in Figure 5 As shown, the affinity of ANXA5 monomer is: Kd=610±245nM and the affinity of ANXA5 dimer is: Kd=191±73nM. It can be seen that compared with the monomer, the affinity of dimer ANXA5 to PS is increased by about 3 times.

[0060] Example 4

[0061] Molecular basis of ANXA5 monomer and dimer binding to PS

[0062] The present invention uses molecular docking to reveal the molecular mechanism of the binding of ANXA5 monomers and dimers to phosphatidylserine (PS). The structures of the protein and PS were completed by the QuickPrep program in the molecular operating environment (MOE). Molecular docking studies were performed using MOE, and the rigid protein and the flexible ligand were docked using the standard docking program. All docking poses were ranked according to their binding energy. The best binding poses of ANXA5 monomers and dimers to PS were analyzed for hydrogen bonds or hydrophobic interactions. The results are shown in Figure 2. Figure 6As shown in Table 2, the binding of PS to monomeric ANXA5 is stronger (-9.62 kcal / mol) than to dimeric ANXA5 (-7.67 kcal / mol). As shown in Table 2, in monomeric ANXA5, the binding of PS is dependent on calcium ions. The ligand oxygen atoms (O, OG, OXT, and O15) interact with 405CA and 407CA through metal or ionic bonds. The ligand nitrogen (N) is 1.30 μg / mol away from OE1 of 35Glu. Form a hydrogen bond (-6.1 kcal / mol). The distance between the ligand oxygen (O18) and the NZ of 310Gly is Form hydrogen bonds (-10.3 kcal / mol). The binding of ANXA5 dimers to PS is independent of calcium ions. Due to the presence of disulfide bonds, in the ANXA5 dimer protein, the two protein molecules exist stably in a mirror-symmetrical manner. This leads to changes in the hydrophilic and hydrophobic interfaces on the surface of the dimeric protein. Compared with monomeric ANXA5, the dimer forms a highly hydrophobic region near the disulfide bond, which promotes the stabilization of the hydrophobic fatty acid side chains in the ligand. In addition, the hydrophilic head group of the ligand interacts extensively with the amino acids in the hydrophilic region of the dimer through hydrogen bonds. It is worth noting that the nitrogen atom of the ligand forms a hydrogen bond with 287Glu (chain B), while the oxygen atom of the ligand interacts with the dimer through hydrogen bonds. The atomic interactions in protein-ligand binding are shown in Table 2:

[0063] Table 2

[0064]

[0065]

[0066] Example 5

[0067] Detection of PS exposure in brain cells specifically labeled by ANXA5 after cerebral ischemia

[0068] In order to verify the specificity of ANXA5 binding to phosphatidylserine, the present invention used an ANXA5 mutant lacking the ability to bind to phosphatidylserine (ANXA5m, whose mutation sites include: R25A, K29S, R63S, D68A, E72Q, D144N, E228A, D303N) as a negative control. The mutant lost the ability to bind to phosphatidylserine (PS) due to the mutation of key amino acids. The results are as follows Figure 7As shown, ANXA5m-Alexa FluorTM 555 has been shown to lack the ability to bind to PS in vitro. In order to study the exposure of phosphatidylserine on brain cells after cerebral ischemia, the present invention induced a 1-hour middle cerebral artery occlusion (MCAO) in adult ICR mice, followed by reperfusion. Then, 24 hours after reperfusion, fluorescently labeled ANXA5 (ANXA5-Alexa FluorTM 555) was injected via the tail vein as a PS exposure imaging agent. 30 minutes after injection, the present invention observed the exposure of PS, indicated by the red fluorescence of ANXA5-Alexa FluorTM 555, which was observed in the ipsilateral ischemic hemisphere, but not in the contralateral hemisphere ( Figure 8 A). In order to further investigate which cells show PS exposure after cerebral ischemia, the present invention co-immunostained brain sections with NeuN, GFAP and Iba1, which are specific markers for neurons, astrocytes and microglia / macrophages, respectively. Due to the high sensitivity of neurons to ischemia, the signal of PS exposure co-localizes with NeuN ( Figure 8 B, 8E). The PS exposed signal also co-localizes with GFAP ( Figure 8 C, 8E), indicating that PS is exposed to astrocytes as early as the acute phase of cerebral ischemia when neuronal PS externalization occurs. In addition, we detected relatively low levels of colocalization of PS signals and the microglia / macrophage marker Iba1 24 hours after ischemia ( Figure 8 C, 8E). However, since microglia / macrophages are phagocytic cells, the colocalization may indicate phagocytosis of PS-exposed cells by microglia / macrophages.

[0069] Example 6

[0070] OGD / R model further validates PS exposure detection on astrocyte surface

[0071] The present invention confirms the ischemia-induced PS exposure on the surface of astrocytes by using an in vitro ischemia model. The present invention simulates the ischemia and reperfusion process in vitro by establishing an OGD / R model. The specific steps are as follows: For astrocyte culture, cortical tissue was collected from 1-day-old newborn mice (C57BL / 6J). The cortical tissue was placed in ice-cold DMEM / F12 culture medium, cut into small pieces, and then digested with EDTA-trypsin for 10 minutes. During the digestion process, DMEM / F12 culture medium containing 10% fetal bovine serum (FBS) was added to terminate the digestion. In order to remove tissue fragments, the cell suspension was filtered through a 50-micron cell filter. The cells were collected and inoculated in a culture bottle pre-coated with poly-D-lysine. The cells changed the culture medium every 2 days. Before each change of the culture medium, the cells with weak attachment to the wall of the culture bottle were blown away. After 9-10 days of in vitro culture, the astrocytes were digested and inoculated on a 24-well plate. The cells were inoculated in a culture bottle / dish for 24 hours to ensure adhesion. The original cell complete culture medium was discarded, and the cells were gently washed three times with sterile PBS, and replaced with sugar-free DMEM culture medium. The cells were cultured in a hypoxic incubator at 37°C and containing 94% N2-1% O2-5% CO2 for 6 hours, i.e., oxygen-glucose deprivation, to simulate the ischemia stage. The sugar-free DMEM culture medium was discarded, the cells were washed with PBS, and high-glucose DMEM complete culture medium was added. The cells were transferred to a 37°C, 5% CO2 incubator and continued to be cultured for 24 hours. This process simulates the reperfusion stage after ischemia. To this end, the present invention subjected primary astrocytes to oxygen-glucose deprivation (OGD) treatment and then reoxidized. PS exposure was detected using ANXA5-Alexa FluorTM 555, and the results were as follows. Fig. 9 As shown, the present invention observed that OGD and reoxygenation induced PS externalization in astrocytes.

[0072] Example 7

[0073] Detection of PS-exposed astrocytes being phagocytosed by microglia after cerebral ischemia

[0074] The exposure of PS on the cell surface determines whether the stressed cells can be recognized and engulfed by phagocytes. The present invention assumes that exposed PS may trigger the engulfment of astrocytes by professional phagocytes, microglia, in the brain. In order to visualize phagocytosis in vivo, the present invention uses microglial lineage tracing mice. In brief, the present invention mates Cx3cr1-CreER mice that specifically express Cre recombinase with Rosa26-tdTomato mice to obtain the Cx3cr1-CreER::Rosa26 lineage. Then, by injecting tamoxifen into Cx3cr1-CreER mice, the expression of tdTomato in microglia is induced. One month after the injection of tamoxifen, the present invention performs a middle cerebral artery occlusion (MCAO) experiment in Cx3cr1-CreER mice, followed by reperfusion. 24 hours after reperfusion, fluorescently labeled ANXA5 (ANXA5-EGFP) was injected into Cx3cr1-CreER mice as a PS imaging agent via the tail vein. The present invention observed that microglia (tdTomato-positive cells) were in close contact with cells exposing PS, as shown by EGFP and tdTomato fluorescence. In addition, the present invention also performed immunostaining on brain sections using GFAP antibodies. Supporting the present invention's hypothesis, a large number of ANXA5-positive and GFAP-positive astrocyte fragments co-localized with tdTomato-positive microglia in the same area 24 hours or 48 hours after reperfusion of the ischemic cortex (see Fig.10 ). Taken together, the results indicate that cerebral ischemia induces PS exposure on astrocytes, and this PS exposure leads to microglia phagocytosis of stressed astrocytes.

[0075] Example 8

[0076] Detection of PS exposure of ANXA5 monomer and dimer in target lesion area after cerebral ischemia

[0077] The present invention uses male ICR mice weighing 25-28 grams purchased from Shanghai Slake Company (China) to establish a MACO model. The specific steps are as follows: the mice are deprived of food and water for 12 hours before surgery, weighed and marked for grouping; by inhaling isoflurane anesthesia (induction concentration 4%, maintenance concentration 1%-1.5%), the mice are fixed in a supine position on an operating table. Pay attention to keeping the mice warm during the modeling process; prepare the skin from the upper part of the sternum to the neck, disinfect, make a longitudinal incision of about 1 cm along the midline of the neck, use ophthalmic forceps to bluntly separate the muscles, fascia and nerves under stereomicroscope observation, free the left common carotid artery (CCA), and tie a slipknot with 6-0 silk thread; separate upward along the CCA to free the internal carotid artery (EAC) and the external carotid artery (ICA). The distal end of the ECA is threaded and ligated together with the thyroid artery. A 6-0 suture is passed between the ligature and the bifurcation of the CCA, and a loose knot is tied. A small incision is made between the loose knot and the ligature with microscissors. After inserting the thread plug, the loose knot is tightened. The force is determined by the thread plug just sliding in the blood vessel without blood flowing out of the rupture. The ECA is cut close to the ligature at the distal end of the ECA, and the angle is adjusted to insert the thread plug into the ICA, and continue to push forward along the ICA until slight resistance is felt. Stop pushing the thread plug. At this time, its front end completely blocks the beginning of the middle cerebral artery. A slipknot is tied at the end of the ECA to fix the thread plug. The subcutaneous tissue and skin are sutured layer by layer and disinfected. After 1 hour of ischemia, the thread plug is pulled outward so that its head end retreats to the ECA to ensure that the CCA blood flow reperfuses to the middle cerebral artery. The suture was re-sutured and disinfected, and 1 ml of normal saline was injected intraperitoneally for fluid replacement. For mice in the sham group, the surgical procedure was the same as above, except that the tip of the suture was inserted into the ICA but the middle cerebral artery was not embolized. The mice were housed in separate cages after surgery, and attention was paid to maintaining body temperature and timely fluid replacement. After 60 minutes of MCAO, the suture was pulled out to achieve reperfusion (75% higher than the baseline).

[0078] To verify whether ANXA5 monomers and dimers target astrocyte PS exudation in the ischemic brain after MCAO, MCAO was induced in wild-type ICR mice. Before reperfusion, ANXA5 monomers, dimers, or vehicle were injected into MCAO mice through the tail vein. 24 hours after reperfusion, ANXA5-Alexa Fluor TM 555. The result is Fig.11 As shown, ANXA5-Alexa Fluor colocalized with GFAP in ischemic brain 30 minutes after injection. TMThe fluorescence intensity of 555 was significantly reduced by the presence of monomeric and dimeric ANXA5. These results indicate that the ANXA5 monomers and dimers of the present invention can target PS on astrocytes in ischemic brain after MCAO, thereby blocking the binding of ANXA5 to PS exposed on astrocytes.

[0079] Example 9

[0080] Detection of ANXA5 monomer and dimer in maintaining blood-brain barrier integrity after cerebral ischemia

[0081] The present invention evaluates the therapeutic effect of monomer and dimer ANXA5 in the mouse MCAO model. The specific steps are as follows: establish a mouse MCAO model according to the operating steps of Example 8. Three hours after reperfusion, the mice were randomly divided into two groups and treated with ANXA5 monomer (0.75 and 1 mg / kg / day) and ANXA5 dimer (0.75 and 1 mg / kg / day), respectively. The destruction of the blood-brain barrier after ischemia was evaluated by the leakage of the vascular tracer EB into the brain parenchyma. The specific steps are as follows: 46 hours after reperfusion, 2% EB (4mL / kg) was injected into the mouse through the tail vein. Two hours after the injection of EB, the mice were perfused with PBS under anesthesia. Subsequently, the brain tissue was collected and homogenized in 50% trichloroacetic acid. After the sample was centrifuged, the supernatant was collected and analyzed by fluorescence spectroscopy at 620nm using Infinite M200 PRO (TECAN, Grodig, Austria) to determine the absorbance of the supernatant. EB extravasation in each sample was quantified using a standard curve and expressed per gram of wet weight tissue.

[0082] The effect of ANXA5 monomer and dimer treatment in post-ischemic mice can be evaluated by brain edema as follows: The brain was collected 48 hours after MCAO and dissected into left and right hemispheres. The wet weight of the hemisphere was weighed and dried in an oven at 80°C for 48 hours, and then weighed again to obtain the dry weight. The edema was evaluated according to the formula: (wet weight-dry weight) / wet weight. The results are expressed as a percentage.

[0083] The present invention found that at 48 hours after MCAO, mice treated with 0.75 mg / kg monomer showed a trend toward reduced EB leakage in the ischemic brain compared with mice receiving vehicle, but there was no significant difference. However, treatment with 0.75 mg / kg ANXA5 dimer significantly reduced EB leakage (see Fig.12 A and 12B). At a dose of 1 mg / kg, both ANXA5 monomer and dimer significantly inhibited the leakage of EB in the ipsilateral cortex and striatum (see Fig.12 C and 12D). These results suggest that ANXA5 dimers are more effective than monomers in protecting BBB damage induced by ischemia-reperfusion.

[0084] The present invention further examined the effects of monomeric and dimeric ANXA5 on post-ischemic edema formation as another indicator of blood-brain barrier disruption. Consistent with the EB leakage results, both monomeric and dimeric ANXA5 at high doses (1 mg / kg) significantly reduced water content in the ischemic hemisphere, showing significant differences compared to the vehicle group. Notably, at low doses (0.75 mg / kg), the dimer was more effective than the monomer in reducing brain edema (see Fig.13 ). In summary, dimeric ANXA5, which has a higher affinity for PS, more effectively protects the integrity of the BBB after cerebral ischemia by targeting PS-exposed astrocytes.

[0085] Example 10

[0086] ANXA5 monomer and dimer inhibit microglial phagocytosis of PS-exposed astrocytes

[0087] To further explore the molecular mechanism by which ANXA5 monomers and dimers improve the integrity of the blood-brain barrier in ischemic mice, we first examined whether ANXA5 monomers and dimers inhibited the behavior of microglia phagocytosing PS-exposed astrocytes. The specific steps were as follows: For the culture of microglia, cortical tissues were collected from 1-day-old newborn mice (C57BL / 6J). The cortical tissues were placed in ice-cold DMEM / F12 medium, cut into small pieces, and then digested with EDTA-trypsin for 10 minutes. During the digestion process, DMEM / F12 medium containing 10% fetal bovine serum (FBS) was added to terminate the digestion. To remove tissue debris, the cell suspension was filtered through a 50-μm cell strainer. The filtered cells were collected and seeded in flasks pre-coated with poly-D-lysine. The culture medium was changed every 3 days. After 14-16 days of in vitro culture, the culture flasks were shaken at 180 rpm for 30 minutes. Then, the suspended microglia were collected and seeded on 24-well plates for subsequent experiments.

[0088] Primary astrocytes were cultured according to the method of Example 6. Mouse primary microglia were incubated overnight on 24-well or 96-well plates. Astrocytes were cultured and treated with hypoxia / deoxyglucose according to the method of Example 6. After labeling with PKH-26 (Sigma-Aldrich) fluorescent probe, hypoxia / deoxyglucose-treated astrocytes were co-cultured with microglia at a ratio of 10:1 for 6 hours, and 250nM ANXA5 monomer or dimer was added. Then, the cells were immunostained with anti-GFAP and anti-IBA1, and the nuclei were stained with DAPI for visualization. Photos were taken using a fluorescence microscope (Zeiss LSM700, Germany).

[0089] In the present invention, GFAP was used to label astrocytes and Iba-1 was used to label microglia. It was observed that the astrocyte fragments after OGD treatment were in close contact with the primary microglia (see Fig.14 A), indicating that microglia engulfed PS-exposed astrocytes after OGD. As expected, the present invention observed that both monomers and dimers inhibited the fragmentation of astrocytes in close contact with primary microglia after OGD treatment (see Fig.14 A) These results indicate that under ischemic conditions, both ANXA5 monomers and dimers can inhibit the phagocytosis of PS-exposed astrocytes by microglia, and the inhibitory effect of dimeric ANXA5 is more significant.

[0090] Embodiment 11

[0091] ANXA5 monomer and dimer enhance astrocyte-vessel coupling after cerebral ischemia in mice

[0092] Furthermore, astrocyte terminals express the water channel protein AQP4, which plays a key role in maintaining vascular integrity and astrocyte-vascular coupling in the central nervous system. Therefore, ANXA5 monomers and dimers inhibit the phagocytosis of PS-exposed astrocytes by microglia, which may enhance astrocyte-vascular coupling after cerebral ischemia. To verify this hypothesis, the specific steps are as follows: First, mice were anesthetized and then perfused with ice-cold PBS and 4% (w / v) paraformaldehyde (PFA) in PBS. Next, the brain was removed and placed in 4% PFA, fixed overnight at 4°C, and then incubated in PBS containing 30% sucrose at 4°C for 48 hours. Then, the brain was cut into 20 μm slices (using a Leica microtome). After three PBS washes, the slices were incubated in PBS containing 0.2% Triton X-100 and 5% BSA for 1 hour at 37°C in a wet box. Subsequently, the sections were washed with PBS and incubated with primary antibodies overnight at 4°C. For immunohistochemistry, the following primary antibodies were used: mouse anti-CD31 (1:50, Proteintech) and anti-AQP4 (1:500, Oasis Biofarm). After incubation with the primary antibodies overnight, the sections were washed with PBS and then incubated with anti-mouse 647 (1:500, Proteintech) secondary antibodies for 2 hours at room temperature in the dark. After washing, the sections were mounted with mounting medium containing DAPI. Finally, images of the brain sections were taken using a Nikon confocal fluorescence microscope.

[0093] The present invention observed that the number of AQP4-positive blood vessels (AQP4 / CD31 double positive) was reduced in the ischemic brain reperfused 24 hours after MCAO (see Fig.14 A large number of vessels in the ischemic hemisphere lack AQP4 expression. However, postischemic treatment with ANXA5 monomer and dimer significantly increased the number of AQP4-positive vessels compared with controls (see Fig.14 B, 14C). Both monomer and dimer treatments enhanced astrocyte-vessel coupling, indicating that both ANXA5 monomer and dimer can maintain the integrity of the blood-brain barrier by increasing the coupling between astrocytes and vessels.

[0094] Example 12

[0095] ANXA5 monomer and dimer reduce extravascular fibrinogen leakage after cerebral ischemia in mice

[0096] Further, the outer vascular fibrinogen was detected as an indicator of blood-brain barrier integrity by immunostaining of fibrinogen and endothelial marker CD31. The specific steps are as follows: brain slices were obtained according to Example 11, and after the slices were washed with PBS three times, they were incubated in PBS containing 0.2% Triton X-100 and 5% BSA at 37°C in a wet box for 1 hour. Then, the slices were washed with PBS and incubated with a primary antibody overnight at 4°C. For immunohistochemistry, the following primary antibodies were used: mouse anti-CD31 (1:50, Proteintech) and anti-Fibrinogen (1:200, Abcam). After the slices were incubated with the primary antibody overnight, they were washed with PBS and then incubated in the dark at room temperature for 2 hours with anti-mouse 647 (1:500, Proteintech) secondary antibodies. After washing, the slices were encapsulated with a mounting medium containing DAPI. Images of brain slices were taken using a Nikon confocal fluorescence microscope.

[0097] The present invention further observed that at 24 hours after MCAO and reperfusion, extravascular fibrinogen leakage was significantly reduced in ANXA5 monomer and dimer treated mice compared with control mice (see Fig.14D, 14E). Fibrinogen leakage is an important hallmark of blood-brain barrier damage, indicating that blood components penetrate into the brain parenchyma, a condition that often leads to cerebral edema and neuronal damage. However, treatment with ANXA5 monomer and dimer significantly reduced extravascular fibrinogen leakage, indicating that ANXA5 monomer and dimer maintain the integrity of the blood-brain barrier by reducing the extravasation of fibrinogen. This finding suggests that ANXA5 monomer and dimer are not only effective in preventing extravascular fibrinogen leakage, but also help to protect and maintain the function of the blood-brain barrier as a whole. In summary, both ANXA5 monomer and dimer can effectively maintain and protect the integrity of the blood-brain barrier of post-ischemic brain tissue by reducing the leakage of extravascular fibrinogen, thereby providing a new therapeutic strategy to deal with blood-brain barrier damage after cerebral ischemia.

[0098] In summary, both ANXA5 monomers and dimers can target astrocytes to mask their engulfment by microglia, and the effect of ANXA5 dimers is better. In addition, both ANXA5 monomers and dimers reduce blood-brain barrier damage after cerebral ischemia by increasing the coupling between astrocytes and blood vessels and reducing extravascular fibrinogen leakage, and ANXA5 dimers are more effective in treating ischemic stroke. The present invention provides a pharmaceutical composition for preventing or treating blood-brain barrier damage after cerebral ischemia and its application. By using monomers and dimers of the phosphatidylserine binding protein ANXA5, the composition can effectively target the exposure of phosphatidylserine on astrocytes, thereby protecting or repairing the blood-brain barrier and avoiding complications such as reperfusion hemorrhage and cerebral edema. The present invention showed significant therapeutic effects in experiments, proving that it has superior performance in reducing blood-brain barrier damage.

[0099] The above shows and describes the basic principles, main features and advantages of the present invention. Those skilled in the art should understand that the present invention is not limited to the above embodiments, and the above embodiments and descriptions are only for explaining the principles of the present invention. Without departing from the spirit and scope of the present invention, the present invention may have various changes and improvements, and the scope of protection of the present invention is defined by the attached claims, description and their equivalents.

Claims

1. A pharmaceutical composition for preventing or treating blood-brain barrier damage after cerebral ischemia, Features: The pharmaceutical composition for preventing or treating blood-brain barrier damage after cerebral ischemia comprises a phosphatidylserine PS binding protein as an active ingredient, wherein the PS binding protein comprises an ANXA5 monomer or an ANXA5 dimer, and the PS binding protein has high affinity for binding to the exposed PS on astrocytes, the amino acid sequence of the ANXA5 monomer is shown in SEQ ID NO.1, and the amino acid sequence of the ANXA5 dimer is shown in SEQ ID NO.

2.

2. The pharmaceutical composition for preventing or treating blood-brain barrier damage after cerebral ischemia according to claim 1, Features: The ANXA5 dimer is formed through a disulfide-linked C-terminal cysteine ​​residue to target PS externalization on astrocytes.

3. The pharmaceutical composition for preventing or treating blood-brain barrier damage after cerebral ischemia according to claim 1, Features: Contains one or more pharmaceutically acceptable carriers or diluents.

4. A method for treating blood-brain barrier damage after cerebral ischemia using the pharmaceutical composition according to any one of claims 1 to 3, Features: Administration was via tail vein injection.

5. A method for evaluating the degree of blood-brain barrier damage after cerebral ischemia, Features: The extent of injury was assessed by detecting the level of PS exposure in brain tissue.

6. The method for evaluating the degree of blood-brain barrier damage after cerebral ischemia according to claim 5, Features: Fluorescently labeled ANXA5 or its dimer was used as an imaging reagent for PS exposure.

7. A method for detecting PS exposure of astrocytes after cerebral ischemia. Features: ANXA5 or its dimer was detected using a probe conjugated with a fluorescent marker.

8. The detection method according to claim 7, Features: PS-exposed astrocytes were observed and quantitatively analyzed by fluorescence microscopy.

9. Use of the pharmaceutical composition according to any one of claims 1 to 3 in the preparation of a drug for preventing or treating blood-brain barrier damage after cerebral ischemia.